Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept

Vera Therapeutics, Inc. (NASDAQ:VERA) is among the 14 best booming stocks to buy right now. On January 7, the company announced that the U.S. Food and Drug Administration (FDA) had accepted Atacicept’s Biologics License Application (BLA) for priority review to treat adult patients of immunoglobulin A nephropathy (IgAN). Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept The application was submitted under the Accelerated Approval Program and has been granted a target action date of ...